Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review

Article type: Research Article

Authors: Pourmontaseri, Hossein^{a; b} | Habibzadeh, Niloofar^c | Entezari, Sarina^d | Samadian, Fatemeh^e | Kiyani, Shamim^f | Taheri, Mina^g | Ahmadi, Ali^h | Fallahi, Mohammad Sadeghⁱ | Sheikhzadeh, Farzad^j | Ansari, Arina^k | Tamimi, Amirhossein^{l; *} | Deravi, Niloofar^{m; *}

Affiliations: [a] Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran | [b] Bitab Knowledge Enterprise, Fasa University of Medical Sciences, Fasa, Iran | [c] Student Research Committee, School of Medical Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | [d] Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [e] Nursing Department, Shahid Beheshti University of Medical Science, Tehran, Iran | [f] Midwifery Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran | [g] Student Research Committee, School of Pharmacy Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | [h] Faculty of Biological Sciences and Technologies, Islamic Azad University Sari Branch, Sari, Iran | [i] School of Medicine, Tehran University of Medical Sciences, Tehran, Iran | [j] Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran | [k] Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. | [l] Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran | [m] Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence: [*] Corresponding authors: Niloofar Deravi, SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, Iran. Tel.: +98 212 243 9770; E-mail: niloofarderavi@sbmu.ac.ir. Amirhossein Tamimi, Central Office of Guilan University of Medical Sciences, Parastar St., Rasht, Iran. Tel.: +98 133 332 4168; E-mail: amirhosseintamimi997@gmail.com.

Abstract: BACKGROUND: Acute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL. METHODS: We gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020. RESULTS: The most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects. CONCLUSION: Appling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field.

Keywords: Monoclonal antibodies, acute lymphocytic leukemia, anti-cancer, targeted therapy

DOI: 10.3233/HAB-211511

Journal: Human Antibodies, vol. 30, no. 3, pp. 117-130, 2022